Avdoralimab |
| Catalog No.GC72391 |
Avdoralimab (IPH 5401) is a fully human IgGκ monoclonal antibody that targets the complement C5a receptor 1 (C5aR1) that prevents its binding to C5a.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2226393-85-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Avdoralimab (IPH 5401) selectively blocks the C5a-C5aR1 interaction and its downstream signaling in human myeloid cells. In vitro, C5aR1 blockade with Avdoralimab (10-30 μg/mL) inhibits C5a-induced neutrophil activation. Avdoralimab blocks the neutrophil activation induced by very high concentrations of C5a. Avdoralimab also inhibits the C5a-induced migration of neutrophils in vitro[1].
In mice with a knock in for human C5aR1 (HuC5aR1 KI mice), Avdoralimab blocks the infiltration of neutrophils and monocytes, prevents albumin release in broncho-alveolar lavage fluid (BALF) and limits C5a-induced acute lung injury (ALI) histopathological features[1].
References:
[1]. Julien Carvelli, et al. Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis. Nature. 2020 Dec;588(7836):146-150.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *